Updates on Blood Cholesterol: Applying new Guidelines to Clinical Practice
- CME / AMA PRA Category 1 Credit™
- CNE / Nursing Contact Hours
- CPE / ACPE Contact Hours
PROGRAM OVERVIEW
Cardiovascular disease is the leading cause of death in the US. While tools have been developed to identify patients at increased risk for atherosclerotic cardiovascular disease (ASCVD), these instruments are not always used in clinical practice. To improve the identification of at-risk patients, in late 2018 the American Heart Association (AHA) and American College of Cardiology (ACC) jointly published guidelines for the use of risk-assessment tools.
In November 2018, the AHA, ACC, and other partnering associations also released a “Guideline on the Management of Blood Cholesterol” to provide updated clinical recommendations for the management of elevated low-density lipoprotein cholesterol (LDL-C), a major contributor to ASCVD.This document provided strategies for primary and secondary prevention of ASCVD, along with approaches for modifying therapy in patients who are not achieving their LDL-C goals.
This activity, Updates on Blood Cholesterol: Applying New Guidelines to Clinical Practice, will review these recent evidence-based recommendations and updates, as well as providing information about non-statin agents recommended for use when patients are not at LDL-C goal.
AGENDA
Welcome and Introductions
Assessing ASCVD Risk – Role of LDL-C
Managing LDL-C to Lower ASCVD Risk
Q&A Session and Activity Roundup
TARGET AUDIENCE
This activity is intended for primary care clinicians, cardiologists, and other clinicians who manage patients who are at risk for or have ASCVD.
EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to:
- Use guideline-recommended tools to evaluate the need for blood cholesterol management for primary ASCVD prevention in patients without clinical ASCVD
- Implement the 2018 cholesterol guidelines when developing individualized primary prevention strategies for patients with and without severe hypercholesterolemia
- Develop management plans for the secondary prevention of ASCVD using recommendations from the 2018 blood cholesterol guidelines
- Intensify LDL-C management using adjunctive non-statin therapy when secondary prevention with statins alone does not achieve 2018 blood cholesterol guideline goals
ACCREDITATION
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association and Rockpointe Corporation. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
For information about the accreditation of this program, please email cme@lipid.org.
CREDIT DESIGNATION
Physicians – The National Lipid Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
FACULTY

Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC
Dr. Morris is a Fellow of the American College of Cardiology, the American Heart Association, the American Society of Preventive Cardiology, and the National Lipid Association. She is on the Executive Committees of the National Lipid Association and the American Board of Clinical Lipidology. She has been selected as Vice-Chair (2019-2020) and Chair (2021-2022) of the American College of Cardiology Annual Scientific Sessions. She also serves as Associate Editor of the Journal of the American College of Cardiology.

Past-President, National Lipid Association
President, American Board of Clinical Lipidology
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and a Fellow and Past-President of the National Lipid Association (NLA). He is a board member for the NLA and the Foundation of the NLA, as well as the President of the American Board of Clinical Lipidology. Dr. Underberg’s clinical interests focus on the management of patients with lipids and lipoprotein disorders, the management of hypertension, and the prevention of cardiovascular disease. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology. He sees patients both at Bellevue Hospital and in a university-based private-practice setting.

Clinical Professor
University of Houston College of Pharmacy
Houston, TX
Dr. Birtcher received her bachelor’s in pharmacy and master’s in pharmacy administration from the University of Texas at Austin. She received her pharmacy doctorate from the University of Florida. She is a certified diabetes educator and board-certified pharmacotherapy specialist with additional qualifications in cardiology. She is an Associate of the American College of Cardiology (ACC) and a Fellow of the National Lipid Association. Dr. Birtcher is an active member of the ACC, having served on many committees, and a member of the Southwest Lipid Association.

Professor of Nursing and Medicine
Nurse Practitioner, Rush Heart Center for Women
LaGrange, IL
Dr. Braun holds a PhD in Nursing Science from the University of Illinois at Chicago. She is board-certified as an Adult Nurse Practitioner from the ANCC and is a Diplomate of the Accreditation Council of Clinical Lipidology. Dr. Braun is a co-investigator for three research grants funded by the NIH and a co-author of five AHA/ACC Scientific Statements, the AHA/ACC statement on Performance Measures for the Primary Prevention of Cardiovascular Disease, and three AHA clinical practice guidelines, including the 2018 Multi-Society Guideline on the Management of Blood Cholesterol. She has served as consultant to the CDC's Division for Heart Disease and Stroke Prevention for several projects.
PHYSICIAN ASSISTANTS CREDIT DESIGNATION
PHARMACISTS CREDIT DESIGNATION
Universal Activity Number JA0007192-9999-19-043-H01-P (Knowledge)
This activity has been approved for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
NURSES CREDIT DESIGNATION
DISCLOSURE STATEMENT
All persons in a position to control the content of a continuing medical education program provided by NLA are required to disclose any relevant financial relationships with any commercial interest to NLA as well as to learners. All conflicts of interest are identified and resolved by NLA in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
FACULTY DISCLOSURES
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA: Consultant: Akcea Therapeutics; Local PI, Clear Outcomes Study: Esperion
James A. Underberg, MD, MS, FNLA: Speaker: Akcea Therapeutics, Alexion, Amarin, Amgen, Regeneron, Sanofi; Advisory Board: Akcea Therapeutics, Alexion, Amarin, Amgen, Regeneron, Sanofi; Consultant: Ambry, Amgen; Contracted Research: Aegerion, Pfizer
Kim K. Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE: Nothing to disclose
Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FNLA, FAANP, FAAN: Nothing to disclose
NON-FACULTY CONTENT CONTRIBUTORS
Terry Ann Glauser, MD, MPH; Blair St. Amand; NLA Staff and Reviewer Scott W. Shurmur, MD, FNLA: Nothing to disclose
FDA DISCLOSURE
SYSTEM REQUIREMENTS
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
PROVIDER
Jointly provided by the National Lipid Association and Rockpointe
SUPPORTER
This activity is supported by educational funding provided by Amgen.
RELATED COURSES

Improving Outcomes for Patients with Severe Hypercholesterolemia
Credits 1.00 (60 min)
Format Webcourse

FIGHTING THE UPHILL BATTLE: Current Evidence in Obesity Management
Credits 1.00 (60 min)
Format Webcourse

Aug